An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris

Phase 2

Completed

Brief Summary: This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in pediatric patients 9 to less than 12 years of age with acne vulgaris. Adrenal suppression effects and systemic safety are an important safety concern. The current study is designed to investigate these potential concerns under maximal use conditions.

Recruitment & Eligibility

Inclusion Criteria

Patient must provide written informed assent and be accompanied by the parent or legal guardian at the time of assent/consent signing. The parent or legal guardian must provide written informed consent for the patient.
Patient has moderate to severe facial acne vulgaris as determined by the Investigator and obvious acne on the trunk (i.e., shoulders, upper chest, and/or back).
Females of childbearing potential must be using highly effective birth control methods with a negative urine pregnancy test (UPT) at study start.
Patient must be in general good health with normal renal function and no clinically relevant abnormalities present at study start.
Patient and parent/guardian are able to communicate with the staff and are willing to comply with study instructions, reside at and/or return to the clinic for required visits.

Exclusion Criteria

Patient is pregnant, lactating, or is planning to become pregnant during the study.
Patient has a Body Mass Index (BMI) for age percentile > 95%.
Patient has any skin or medical condition, including facial hair that could interfere with the evaluation of the test article or requires the use of interfering topical or systemic therapy.
Patient has received an investigational drug or been treated with an investigational device within 30 days prior to study start.
Patient is currently enrolled in an investigational drug or device study.
Patient has any condition which, in the investigator's opinion, would make it unsafe for the patient to participate in this research study.
Patient has known allergy or sensitivity to CB-03-01 or any of its ingredients
Patient has participated in a previous CB-03-01 study.

Arm && Interventions

Group	Intervention	Description
CB-03-01 cream, 1%	cortexolone 17α-propionate	Topical CB-03-01 (cortexolone 17α-propionate) cream containing 1% active drug applied to the face and trunk twice daily for 14 days

Primary Outcome Measures

Name	Time	Method
Change in HPA Axis Response as Measured by CST	Pre- and Post-CST on Day 14	Measurement of serum cortisol concentrations after stimulation of the adrenal cortex with cosyntropin (Cosyntropin Stimulation Test - CST). HPA axis suppression is defined as a post-stimulation serum cortisol level ≤ 18 μg/dL at Day 14.

Secondary Outcome Measures

Name	Time	Method
Evaluate Trough Plasma Concentrations	14 Days	Trough (single blood draw approximately 12 hours post the most recent dose) measurements of cortexolone 17α-propionate (clascoterone) concentration in plasma at Screening, Baseline, Day 7 and Day 14.

Locations (10): Site 103
🇺🇸
Fort Smith, Arkansas, United States
Site 101
🇺🇸
San Diego, California, United States
Site 102
🇺🇸
Houston, Texas, United States
Site 4811
🇵🇱
Katowice, Poland
Site 4812
🇵🇱
Szczecin, Poland
Site 4817
🇵🇱
Tarnów, Poland
Site 4815
🇵🇱
Kraków, Poland
Site 4816
🇵🇱
Rzeszów, Poland
Site 4814
🇵🇱
Czestochowa, Poland
Site 4813
🇵🇱
Kraków, Poland